| Medical and Health Sciences | Lifetime | 723 | FR 13 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 798 | FR 25 | 99.82 |
| Hematology | Lifetime | 14 | FR 1 | 99.92 |
| Medical Genetics | Lifetime | 50 | FR 2 | 99.63 |
| Hematology | 2021-2025 | 16 | FR 1 | 99.69 |
| Medical Genetics | 2021-2025 | 90 | FR 4 | 97.13 |
| Rheumatology | 2021-2025 | 385 | FR 18 | 84.08 |
| Acute Myeloid Leukemia Research | Lifetime | 7 | FR 1 | 99.95 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 7 | FR 1 | 99.86 |
| Retinoids in leukemia and cellular processes | Lifetime | 8 | FR 2 | 99.83 |
| Histone Deacetylase Inhibitors Research | Lifetime | 23 | FR 1 | 99.68 |
| Acute Lymphoblastic Leukemia research | Lifetime | 50 | FR 3 | 99.70 |
| Hematological disorders and diagnostics | Lifetime | 21 | FR 1 | 99.44 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 107 | FR 6 | 99.65 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 58 | FR 2 | 99.65 |
| Hemoglobinopathies and Related Disorders | Lifetime | 73 | FR 2 | 99.22 |
| Multiple Myeloma Research and Treatments | Lifetime | 73 | FR 8 | 99.49 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 132 | FR 6 | 99.30 |
| Neutropenia and Cancer Infections | Lifetime | 68 | FR 5 | 99.16 |
| Blood disorders and treatments | Lifetime | 70 | FR 5 | 98.65 |
| Protein Degradation and Inhibitors | Lifetime | 164 | FR 9 | 98.66 |
| Sarcoma Diagnosis and Treatment | Lifetime | 324 | FR 21 | 98.67 |
| Lymphoma Diagnosis and Treatment | Lifetime | 564 | FR 40 | 98.58 |
| Drug-Induced Ocular Toxicity | Lifetime | 24 | FR 2 | 97.46 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 313 | FR 15 | 98.24 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 92 | FR 9 | 97.15 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 226 | FR 22 | 97.21 |
| Platelet Disorders and Treatments | Lifetime | 633 | FR 42 | 96.91 |
| Bone and Joint Diseases | Lifetime | 479 | FR 25 | 96.38 |
| Antioxidant Activity and Oxidative Stress | Lifetime | 670 | FR 23 | 96.28 |
| Eosinophilic Disorders and Syndromes | Lifetime | 677 | FR 53 | 95.44 |
| Vascular Tumors and Angiosarcomas | Lifetime | 627 | FR 35 | 93.08 |
| Erythropoietin and Anemia Treatment | Lifetime | 578 | FR 21 | 92.40 |
| Kruppel-like factors research | Lifetime | 967 | FR 28 | 86.68 |
| Acute Myeloid Leukemia Research | 2021-2025 | 14 | FR 1 | 99.81 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 29 | FR 3 | 99.28 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 53 | FR 2 | 97.83 |
| Neutropenia and Cancer Infections | 2021-2025 | 33 | FR 4 | 97.14 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 141 | FR 9 | 97.39 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 121 | FR 4 | 93.06 |
| Hematopoietic Stem Cell Transplantation | 2021-2025 | 294 | FR 13 | 94.88 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 462 | FR 26 | 93.17 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 500 | FR 22 | 93.24 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 69 | FR 19 | 92.61 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 825 | FR 61 | 84.13 |
| Hematological disorders and diagnostics | 2021-2025 | 173 | FR 3 | 79.51 |
| Blood disorders and treatments | 2021-2025 | 348 | FR 18 | 77.28 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 330 | FR 4 | 71.46 |
| Vascular Anomalies and Treatments | 2021-2025 | 383 | FR 59 | 65.34 |
| Histiocytic Disorders and Treatments | 2021-2025 | 305 | FR 36 | 62.38 |
